Ashley Vachon
Gastroenterology · Lone Tree, CONPI 1184042582
Payments from drug & device makers
Across 46 payments — averaging $35.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$852
- Lilly USA, LLC$139
- Takeda Pharmaceuticals U.S.A., Inc.$124
- Sanofi$96
- Pfizer$86
- Gilead$57
- plus $259 from 10 others
What the payments were for
- Food & beverage$1,60099%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $852 |
| Lilly USA, LLC | 2 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $124 |
| Sanofi | 4 | $96 |
| Pfizer | 4 | $86 |
| Gilead | 3 | $57 |
| Axonics, Inc. | 1 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| Bristol Myers Squibb | 2 | $39 |
| Ardelyx, Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Celltrion USA Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Intercept Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,615 in reported general payments places this provider in the 45th percentile of 304 gastroenterology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SutabSod Sulf/Pot Chloride/Mag Sulf | 63 | $10,426 |
| Pantoprazole Sodium | 91 | $1,858 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 11 | $1,389 |
| Omeprazole | 58 | $1,302 |
| Ondansetron OdtOndansetron | 14 | $392 |
| Famotidine | 30 | $316 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 13 | $180 |
| Dicyclomine Hcl | 15 | $66 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Lone Tree
- Matthew NicholsLone Tree$396K
- Nathan SchomakerLone Tree$344K
- Christopher ShepelaLone Tree$64K
- Blake NiccumLone Tree$15K
- Bhaktasharan PatelColorado Springs$22M
- Marcelo KugelmasEnglewood$2.7M
- Douglas AdlerColorado Springs$1.2M
- Masi KhajaGrand Junction$1.2M
- Peter McNallyFt Carson$1.1M
- Mark GerichAurora$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.